Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma.
about
Systemic therapy for cutaneous T-cell lymphoma: who, when, what, and why?The utility of bexarotene in mycosis fungoides and Sézary syndrome.Long-term outcome of patients with advanced-stage cutaneous T cell lymphoma treated with gemcitabine.Copper-catalyzed α-selective hydrostannylation of alkynes for the synthesis of branched alkenylstannanes.A masked diboron in Cu-catalysed borylation reaction: highly regioselective formal hydroboration of alkynes for synthesis of branched alkenylborons.
P2860
Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phase II study of gemcitabine ...... of cutaneous T-cell lymphoma.
@en
Phase II study of gemcitabine and bexarotene
@nl
type
label
Phase II study of gemcitabine ...... of cutaneous T-cell lymphoma.
@en
Phase II study of gemcitabine and bexarotene
@nl
prefLabel
Phase II study of gemcitabine ...... of cutaneous T-cell lymphoma.
@en
Phase II study of gemcitabine and bexarotene
@nl
P2093
P2860
P356
P1476
Phase II study of gemcitabine ...... of cutaneous T-cell lymphoma.
@en
P2093
J Scarisbrick
S Whittaker
P2860
P2888
P304
P356
10.1038/BJC.2013.616
P407
P577
2013-10-17T00:00:00Z
P5875
P6179
1013452819